Microscopic colitis is a chronic inflammatory bowel disease characterized by persistent watery diarrhea, normal-appearing colonic mucosa on endoscopy, and characteristic histopathological findings on biopsy. It affects approximately 10–20 per 100,000 person-years, predominantly in women over 50, and is one of the most common causes of chronic non-bloody diarrhea in older adults. [1] Despite its prevalence, microscopic colitis remains underdiagnosed — many patients endure years of symptoms before a colonoscopy with biopsy provides the correct diagnosis.

Two subtypes, one clinical picture. Microscopic colitis encompasses two histological variants: collagenous colitis, defined by a thickened subepithelial collagen band (>10 μm), and lymphocytic colitis, characterized by increased intraepithelial lymphocytes without collagen thickening. [2] Clinically, both present similarly — chronic watery diarrhea, often nocturnal, with urgency, abdominal cramping, and weight loss. The distinction is histological, not clinical, and treatment approaches are largely the same.

Where conventional treatment falls short. First-line therapy is budesonide — a locally acting corticosteroid — which achieves clinical remission in approximately 80% of patients. [3] However, relapse after discontinuation is common, affecting 60–80% of responders within months. [4] Second-line options — including loperamide, bismuth subsalicylate, cholestyramine, and immunosuppressants such as azathioprine or methotrexate — offer variable efficacy and carry their own side-effect burdens. For patients with steroid-dependent or steroid-refractory disease, the therapeutic options narrow considerably. Anti-TNF biologics have shown some efficacy in small series, but evidence is limited and access is variable.

The tissue-level problem. The fundamental pathology in microscopic colitis is a dysregulated mucosal immune response to luminal antigens, resulting in chronic T-cell-mediated inflammation of the colonic epithelium. [5] Increased CD8+ intraepithelial lymphocytes, mucosal Th1/Th17 skewing, and epithelial barrier dysfunction are core features. [6] Nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), and selective serotonin reuptake inhibitors (SSRIs) have been implicated as triggers or exacerbating factors in susceptible individuals. [7] MSC therapy is being investigated as a potential disease-modifying approach that targets the underlying immune dysregulation rather than simply suppressing symptoms.

Why mesenchymal stem cells are studied for microscopic colitis

MSCs exert a broad immunomodulatory program that is particularly well-suited to the immunopathology of microscopic colitis. When exposed to an inflamed colonic environment, MSCs secrete anti-inflammatory mediators — including TGF-β, IL-10, PGE2, TSG-6, and indoleamine 2,3-dioxygenase (IDO) — that shift macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype, suppress effector T-cell proliferation, and expand regulatory T-cell populations. [8][9]

Reversing the Th1/Th17 skew. Microscopic colitis is driven by a Th1/Th17-predominant immune response, with elevated levels of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-17 (IL-17) in the colonic mucosa. [10] MSCs suppress Th1 and Th17 differentiation while promoting Treg expansion through secretion of TGF-β and PGE2 — effectively rebalancing the mucosal immune environment away from chronic inflammation. [11] This mechanism directly addresses the CD8+ lymphocyte-driven epithelial injury that defines the condition.

Restoring epithelial barrier integrity. The colonic epithelium in microscopic colitis exhibits increased permeability, contributing to the translocation of luminal antigens that perpetuate the inflammatory cycle. [12] MSCs upregulate tight junction proteins — including occludin, claudin-1, and ZO-1 — and promote epithelial proliferation through secretion of keratinocyte growth factor (KGF), epidermal growth factor (EGF), and hepatocyte growth factor (HGF). [13] Restoration of barrier function may reduce the antigenic drive that sustains colonic mucosal inflammation.

Targeting the collagen band in collagenous colitis. The thickened subepithelial collagen band in collagenous colitis reflects excessive extracellular matrix deposition by activated myofibroblasts. [14] MSCs possess anti-fibrotic properties through modulation of the TGF-β/Smad signaling pathway, matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) balance, and suppression of myofibroblast activation. [15] While direct evidence in collagenous colitis is lacking, the anti-fibrotic potential of MSCs is well-documented in other gastrointestinal fibrotic conditions.

Key MSC mechanisms relevant to microscopic colitis

  • Th1/Th17 suppression + Treg expansion — rebalances mucosal adaptive immunity
  • M1→M2 macrophage polarization — shifts colonic immune environment from inflammatory to reparative
  • Epithelial barrier restoration — tight junction protein upregulation reduces gut permeability
  • Anti-fibrotic activity — TGF-β/Smad modulation may reduce collagen band thickness in collagenous colitis
  • CD8+ T-cell suppression — directly targets the intraepithelial lymphocytosis that defines the disease

What the clinical evidence says

The direct evidence is early. No large randomized controlled trial has specifically tested MSC therapy for microscopic colitis. However, the evidence base from related gastrointestinal inflammatory conditions — and from the broader MSC immunomodulation literature — provides a biologically plausible foundation.

Evidence from IBD trials. The most relevant clinical data comes from trials of MSC therapy in Crohn's disease and ulcerative colitis. Allogeneic MSCs (darvadstrocel / Cx601) received EMA approval for complex perianal fistulas in Crohn's disease based on the ADMIRE-CD trial, which demonstrated a significant improvement in combined remission at 24 weeks versus placebo. [16] Systemic MSC infusion for luminal Crohn's and ulcerative colitis has shown safety and modest efficacy signals in early-phase trials, with reductions in endoscopic disease activity and inflammatory biomarkers in some patients. [17]

Gut-specific immunomodulation. Intravenously infused MSCs exhibit tropism for sites of inflammation, including the gastrointestinal tract, through expression of chemokine receptors (CCR2, CCR4, CXCR4) that respond to inflammatory chemokine gradients. [18] Once localized to the inflamed colon, MSCs exert paracrine effects — secreting anti-inflammatory mediators and growth factors — without requiring long-term engraftment. This "hit-and-run" mechanism is well-suited to a condition like microscopic colitis, where chronic, low-grade inflammation is the primary pathology rather than structural tissue loss.

Case reports and clinical experience. A small number of case reports have described the use of MSC therapy in patients with refractory microscopic colitis, with outcomes including reductions in stool frequency, improvements in quality-of-life scores, and reductions in corticosteroid dependence. These are anecdotal and subject to publication bias — they do not constitute a formal evidence base. However, they are consistent with the mechanism of action and the safety profile observed in larger IBD cohorts.

How MSC therapy is delivered for gastrointestinal conditions

Intravenous (IV) infusion is the standard route. For systemic colonic conditions like microscopic colitis, MSCs are typically delivered via a peripheral intravenous infusion over 30–60 minutes. The cells travel through the pulmonary circulation and distribute to sites of active inflammation via chemokine-directed homing. This approach is non-invasive, well-tolerated, and does not require bowel preparation or endoscopic access.

What to expect during treatment. The infusion itself is straightforward. A standard IV line is placed, and the MSC suspension is administered in a clinical setting with vital-sign monitoring. Most patients experience no immediate symptoms. A small proportion may experience a mild, transient infusion reaction — typically a low-grade temperature elevation or mild flushing — that resolves within an hour. Patients return to normal activities the following day. There is no recovery period, no sedation, and no dietary restriction beyond the usual pre-IV hydration.

Treatment frequency and dosing. There is no established protocol specifically for microscopic colitis. In clinical experience with related gastrointestinal inflammatory conditions, a single intravenous infusion is the most common starting point, with repeat infusions at 3–6 month intervals guided by clinical response, stool frequency, and inflammatory biomarker trends. The total number of infusions is individualized — some patients achieve sustained improvement after a single treatment, while others benefit from periodic booster infusions.

What MSC therapy does NOT do for microscopic colitis

  • Does not provide immediate symptom relief — immunomodulatory effects develop over weeks, not hours
  • Does not eliminate the need for diagnostic colonoscopy — histological confirmation remains essential
  • Does not replace budesonide for acute flares — MSC therapy targets the chronic inflammatory substrate, not acute exacerbations
  • Does not cure the condition — the goal is disease modification and reduced pharmacotherapy dependence, not permanent remission in all cases

Recovery and expected timeline

MSC therapy is an outpatient procedure. Following the infusion, most patients return to normal activities within 24 hours. The timeline for symptomatic improvement in gastrointestinal conditions is gradual:

Week 1–2

Most patients notice no immediate change. Occasional mild fatigue or transient low-grade temperature. The immunomodulatory program is initiating — MSCs are engaging macrophages, T-cells, and the epithelial repair machinery at the cellular level. No acute symptom improvement should be expected during this phase.

Week 4–8

This is when initial clinical signals typically emerge. Some patients report gradual reductions in stool frequency and urgency, with improvements in abdominal comfort. The anti-inflammatory effects — macrophage polarization, Treg expansion, Th1/Th17 suppression — are becoming clinically apparent.

Month 3–6

The period of maximal immunomodulatory effect. Most responders see substantial reductions in diarrhea frequency and improvements in quality of life. Corticosteroid tapering may be possible under medical supervision. This is the typical window for assessing whether a repeat infusion is indicated.

Month 6–12

Sustained responders maintain reduced stool frequency and improved quality of life. The goal during this period is durable disease modification — reduced pharmacotherapy dependence, fewer corticosteroid courses, and stable or improved colonic mucosal histology on follow-up biopsy. Repeat infusions may be considered for patients with partial or waning responses.

How to evaluate a clinic for microscopic colitis treatment

Choosing where to receive MSC therapy — particularly for a condition where the evidence base is still emerging — requires careful due diligence. Several markers distinguish legitimate clinical providers from those that prioritize marketing over medicine:

Frequently Asked Questions

How much does stem cell therapy for microscopic colitis cost in Thailand?

A single IV MSC infusion in Thailand typically ranges from USD 8,000 to 15,000, depending on cell dose, laboratory standards, and the clinic's infrastructure. This is substantially lower than equivalent treatment in the United States or Europe, where costs can exceed USD 25,000–40,000 per infusion. Patients should prioritize quality and transparency over cost alone — the lowest price often reflects corners cut in cell manufacturing or quality control.

Is stem cell therapy for microscopic colitis safe?

MSC therapy has an established safety record across thousands of patients treated in clinical trials for gastrointestinal, autoimmune, and inflammatory conditions. The most common side effects are mild and transient — fatigue, low-grade fever, or infusion-related symptoms lasting 24–48 hours. [20] Serious adverse events related to the MSC product itself are rare. However, the long-term safety data beyond 5–10 years remains limited, and patients should be informed of this uncertainty.

Can MSC therapy replace budesonide for microscopic colitis?

MSC therapy is not a replacement for acute pharmacotherapy. Budesonide remains the first-line treatment for active microscopic colitis and achieves high rates of clinical remission. MSC therapy is being investigated as a disease-modifying strategy for patients with steroid-dependent or frequently relapsing disease — potentially reducing the need for long-term corticosteroid exposure and interrupting the cycle of relapse and remission.

How long does it take to see results from MSC therapy?

Symptomatic improvement in gastrointestinal inflammatory conditions typically becomes apparent between 4 and 12 weeks after infusion, with the maximal effect developing over 3–6 months. This gradual timeline reflects the immunomodulatory mechanism — MSCs do not provide immediate symptom relief but rather reprogram the mucosal immune environment toward a less inflammatory state. Some patients may see earlier improvements; others may require a second infusion to achieve a clinically meaningful response.

Which microscopic colitis subtype responds better to MSC therapy?

There is no clinical data comparing MSC therapy outcomes between collagenous colitis and lymphocytic colitis specifically. Both subtypes share a common immunopathological substrate — T-cell-mediated inflammation of the colonic epithelium — suggesting that MSCs' broad immunomodulatory effects should be applicable to both. The anti-fibrotic properties of MSCs may offer additional theoretical benefit in collagenous colitis, where the thickened subepithelial collagen band is a defining histological feature, but this remains speculative.

Limitations and honest caveats

Several important limitations must be stated plainly. First, MSC therapy for microscopic colitis is investigational — it has not been validated in a randomized controlled trial for this specific indication. The evidence supporting its use is drawn from mechanistic plausibility, preclinical models of colonic inflammation, clinical experience in related gastrointestinal inflammatory conditions (Crohn's disease, ulcerative colitis), and a small number of anecdotal case reports — not from microscopic colitis-specific clinical trials. Patients considering this treatment must understand that the benefit is unproven for this indication.

Second, not every patient will respond. Even in conditions where the evidence base is stronger, a proportion of patients show no clinically meaningful improvement after MSC infusion. Predictors of response in gastrointestinal conditions are not well-characterized, and it is not currently possible to identify in advance who is most likely to benefit.

Third, MSC therapy does not cure microscopic colitis. The goal is disease modification — reducing the frequency and severity of symptoms, decreasing dependence on corticosteroids and other pharmacotherapy, and improving quality of life — not permanent remission in all cases. Budesonide, dietary modification, and specialist gastroenterological follow-up remain essential components of management.

Fourth, the cost is substantial and not covered by insurance. MSC therapy for microscopic colitis is a self-funded treatment. Patients should carefully consider the financial implications alongside the uncertain benefit before proceeding.

Fifth, long-term safety data beyond 5–10 years of follow-up are limited for MSC therapy in general, and essentially nonexistent for microscopic colitis specifically. While the short-to-medium-term safety profile is reassuring, the possibility of late adverse effects cannot be excluded. Patients must weigh these uncertainties against the potential for disease modification — particularly if they have exhausted conventional therapeutic options and face a future of chronic corticosteroid exposure or biologic therapy.

Sixth, the trigger avoidance component remains critical. NSAIDs, PPIs, SSRIs, and smoking have all been implicated in the development and exacerbation of microscopic colitis. MSC therapy cannot compensate for ongoing exposure to recognized triggers. A comprehensive management plan must include identification and elimination of modifiable risk factors alongside any cellular intervention.

References

  1. Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. American Journal of Gastroenterology. 2015;110(2):265-276. doi:10.1038/ajg.2014.431 ↩
  2. Münch A, Aust D, Bohr J, et al. Microscopic colitis: current status, present and future challenges. Journal of Crohn's and Colitis. 2012;6(9):932-945. doi:10.1016/j.crohns.2012.05.014 ↩
  3. Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology. 2014;146(5):1222-1230. doi:10.1053/j.gastro.2014.01.019 ↩
  4. Miehlke S, Madisch A, Vinter-Jensen L, et al. Budesonide for maintenance of clinical remission in collagenous colitis: a randomized, placebo-controlled, 12-month trial. Gut. 2016;65(1):47-56. doi:10.1136/gutjnl-2014-308363 ↩
  5. Pisani LF, Tontini GE, Vecchi M, Pastorelli L. Microscopic colitis: what do we know about pathogenesis? Inflammatory Bowel Diseases. 2016;22(2):450-458. doi:10.1097/MIB.0000000000000628 ↩
  6. Kumawat AK, Strid H, Tysk C, Bohr J, Hörnquist EH. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Molecular Immunology. 2013;55(3-4):355-364. doi:10.1016/j.molimm.2013.03.007 ↩
  7. Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Alimentary Pharmacology & Therapeutics. 2016;43(9):1004-1013. doi:10.1111/apt.13583 ↩
  8. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  9. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  10. Carrasco A, Fernández-Bañares F, Pedrosa E, et al. Immunological differences between lymphocytic and collagenous colitis. Journal of Crohn's and Colitis. 2016;10(9):1055-1066. doi:10.1093/ecco-jcc/jjw058 ↩
  11. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. 2011;2(4):34. doi:10.1186/scrt75 ↩
  12. Barmeyer C, Erko I, Fromm A, et al. Ion transport and barrier function are disturbed in microscopic colitis. Annals of the New York Academy of Sciences. 2012;1258:143-148. doi:10.1111/j.1749-6632.2012.06531.x ↩
  13. Watanabe S, Arimura Y, Nagaishi K, et al. Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors. Journal of Gastroenterology. 2014;49(2):270-282. doi:10.1007/s00535-013-0807-8 ↩
  14. Günther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. 2013;62(7):1062-1071. doi:10.1136/gutjnl-2011-301364 ↩
  15. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  16. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016;388(10051):1281-1290. doi:10.1016/S0140-6736(16)31203-X ↩
  17. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12):1662-1669. doi:10.1136/gut.2010.215152 ↩
  18. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206-216. doi:10.1016/j.stem.2009.02.001 ↩
  19. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  20. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩